Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study.

ABSTRACT:

Background

Adrenocortical carcinoma (ACC) is a rare disease with a poor response to chemotherapy. Cisplatin is the most widely investigated drug in the treatment of ACC and in vitro studies have indicated activity of taxanes. The objectives of this study were to evaluate the efficacy and toxicity of cisplatin combined with docetaxel as first-line treatment of advanced ACC.

Methods

Patients with advanced ACC were included in this phase II trial investigating the response to a combination of cisplatin (50 mg m(-2)) and docetaxel (60 mg m(-2)) administered with a 3-week interval.

Results

Nineteen patients were included in this study. The response rate was 21% (95% CI: 3-39%). No patients obtained a complete response, 32% had stable disease, and 37% progressed while on tr

SUBMITTER: Urup T 

PROVIDER: S-EPMC3670472 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature